|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
|
Hodgkin Disease
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Adult Diffuse Large B-Cell Lymphoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
"The role of next-generation sequencing to determine appropriateness of anti-PD1/PD-L1 therapy needs further investigation, but has shown promise in predicting response and survival in melanoma and urothelial carcinoma."
|
28861116 |
2017 |
|
Carcinoma, Transitional Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
"The role of next-generation sequencing to determine appropriateness of anti-PD1/PD-L1 therapy needs further investigation, but has shown promise in predicting response and survival in melanoma and urothelial carcinoma."
|
28861116 |
2017 |
|
Urothelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
"The role of next-generation sequencing to determine appropriateness of anti-PD1/PD-L1 therapy needs further investigation, but has shown promise in predicting response and survival in melanoma and urothelial carcinoma."
|
28861116 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b> Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy.<i>Cancer Discov; 8(9); 1066-8.
|
30181171 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<b> Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy.<i>Cancer Discov; 8(9); 1066-8.
|
30181171 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aim:</b> PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes were constructed for enhanced therapeutic efficacy against gastric cancer.
|
31290727 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aims</b>: Immunohistochemistry of PD-L1 has been recently established as a surrogate method to predict if immunotherapy targeting PD-L1/PD-1 has a significant effect on suppression of cancers such as lung non-small cell carcinoma, melanoma, and renal cell carcinoma.
|
30588196 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aims</b>: Immunohistochemistry of PD-L1 has been recently established as a surrogate method to predict if immunotherapy targeting PD-L1/PD-1 has a significant effect on suppression of cancers such as lung non-small cell carcinoma, melanoma, and renal cell carcinoma.
|
30588196 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aims</b>: Immunohistochemistry of PD-L1 has been recently established as a surrogate method to predict if immunotherapy targeting PD-L1/PD-1 has a significant effect on suppression of cancers such as lung non-small cell carcinoma, melanoma, and renal cell carcinoma.
|
30588196 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Background</b>: Programmed Cell Death 1-Ligand 1 (PD-L1) and Programmed Death Protein 1 (PD-1) blocking antibodies are promising immunotherapies for malignancies.
|
29147606 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Background:</b> Tumor PD-L1 levels have predictive value in PD-1/PD-L1 checkpoint blockade therapies, yet biopsies can only provide baseline information.
|
29900038 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Background:</b> Immunotherapy that targets programmed death protein-1 (PD-1) provides improved treatment efficacy and survival in patients with metastatic non-small cell lung cancer (NSCLC), especially those with high tumor expression of PD-L1.
|
29805708 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Background:</b> Interaction of the programmed death receptor 1 (PD-1) and its ligand, PD-L1, suppresses T cell activity and permits tumors to evade T cell-mediated immune surveillance.
|
30214445 |
2018 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Predictive biomarkers for immunotherapy in lung cancer are intensively investigated; however, correlations between PD-L1/PD-1 expressions and clinical features or histopathological tumor characteristics determined on hematoxylin and eosin stained sections have not extensively been studied.
|
31002007 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Predictive biomarkers for immunotherapy in lung cancer are intensively investigated; however, correlations between PD-L1/PD-1 expressions and clinical features or histopathological tumor characteristics determined on hematoxylin and eosin stained sections have not extensively been studied.
|
31002007 |
2019 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Predictive biomarkers for immunotherapy in lung cancer are intensively investigated; however, correlations between PD-L1/PD-1 expressions and clinical features or histopathological tumor characteristics determined on hematoxylin and eosin stained sections have not extensively been studied.
|
31002007 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Case presentation:</b> A 66-year-old gentleman with metastatic non-small-cell lung cancer developed a wide-based gait following treatment on a clinical trial with cytotoxic chemotherapy and an anti-PD-L1 drug.
|
31414604 |
2019 |
|
Allergic rhinitis (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion</b>: PD-L1 may have a protective role against allergic rhinitis, although the precise mechanism requires further detailed studies.
|
31269820 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> PD-L1 negative expression in TC at 25% or 50% cutoff values was the independent predictor for longer postsurgical survival time in both NSCLC samples and NSCLC samples with TIL.
|
29187883 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> PD-L1 monoclonal antibody-conjugated immunoliposomes have immense potential to be applied as a next-generation nanomedicine for PD-L1-positive gastric cancers.
|
31290727 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Clinical factors associated with NSCLC microenvironment types based on PD-L1/TIL differed a lot across different types.
|
29290777 |
2018 |